These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 22348778)

  • 1. Deciphering the mystery of thalidomide teratogenicity.
    Ito T; Handa H
    Congenit Anom (Kyoto); 2012 Mar; 52(1):1-7. PubMed ID: 22348778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a primary target of thalidomide teratogenicity.
    Ito T; Ando H; Suzuki T; Ogura T; Hotta K; Imamura Y; Yamaguchi Y; Handa H
    Science; 2010 Mar; 327(5971):1345-50. PubMed ID: 20223979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teratogenic effects of thalidomide: molecular mechanisms.
    Ito T; Ando H; Handa H
    Cell Mol Life Sci; 2011 May; 68(9):1569-79. PubMed ID: 21207098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Thalidomide teratogenicity and its direct target identification].
    Ito T; Ando H; Handa H
    Nihon Rinsho; 2015 Jan; 73(1):143-8. PubMed ID: 25626320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The teratogenic effects of thalidomide on limbs.
    Vargesson N
    J Hand Surg Eur Vol; 2019 Jan; 44(1):88-95. PubMed ID: 30335598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Molecular Mechanisms of Thalidomide Teratogenicity and Implications for Modern Medicine.
    Knobloch J; Jungck D; Koch A
    Curr Mol Med; 2017; 17(2):108-117. PubMed ID: 28429672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs.
    Ito T; Handa H
    Int J Hematol; 2016 Sep; 104(3):293-9. PubMed ID: 27460676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.
    Lu G; Middleton RE; Sun H; Naniong M; Ott CJ; Mitsiades CS; Wong KK; Bradner JE; Kaelin WG
    Science; 2014 Jan; 343(6168):305-9. PubMed ID: 24292623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanisms of thalidomide and its derivatives.
    Ito T; Handa H
    Proc Jpn Acad Ser B Phys Biol Sci; 2020; 96(6):189-203. PubMed ID: 32522938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of novel cereblon modulators and their target molecules].
    Ito T
    Rinsho Ketsueki; 2022; 63(6):573-579. PubMed ID: 35831190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate.
    Matyskiela ME; Couto S; Zheng X; Lu G; Hui J; Stamp K; Drew C; Ren Y; Wang M; Carpenter A; Lee CW; Clayton T; Fang W; Lu CC; Riley M; Abdubek P; Blease K; Hartke J; Kumar G; Vessey R; Rolfe M; Hamann LG; Chamberlain PP
    Nat Chem Biol; 2018 Oct; 14(10):981-987. PubMed ID: 30190590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thalidomide-induced teratogenesis: history and mechanisms.
    Vargesson N
    Birth Defects Res C Embryo Today; 2015 Jun; 105(2):140-56. PubMed ID: 26043938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalidomide: chemistry, therapeutic potential and oxidative stress induced teratogenicity.
    Kumar N; Sharma U; Singh C; Singh B
    Curr Top Med Chem; 2012; 12(13):1436-55. PubMed ID: 22650376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thalidomide Inhibits Human iPSC Mesendoderm Differentiation by Modulating CRBN-dependent Degradation of SALL4.
    Belair DG; Lu G; Waller LE; Gustin JA; Collins ND; Kolaja KL
    Sci Rep; 2020 Feb; 10(1):2864. PubMed ID: 32071327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thalidomide: the tragedy of birth defects and the effective treatment of disease.
    Kim JH; Scialli AR
    Toxicol Sci; 2011 Jul; 122(1):1-6. PubMed ID: 21507989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Discovery of the target for immunomodulatory drugs (IMiDs)].
    Ito T; Ando H; Handa H
    Rinsho Ketsueki; 2016 May; 57(5):556-62. PubMed ID: 27263779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The molecular mechanism of thalidomide analogs in hematologic malignancies.
    Lindner S; Krönke J
    J Mol Med (Berl); 2016 Dec; 94(12):1327-1334. PubMed ID: 27492707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRL4-Cereblon complex in Thalidomide Embryopathy: a translational investigation.
    Kowalski TW; Gomes JDA; Garcia GBC; Fraga LR; Paixao-Cortes VR; Recamonde-Mendoza M; Sanseverino MTV; Schuler-Faccini L; Vianna FSL
    Sci Rep; 2020 Jan; 10(1):851. PubMed ID: 31964914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Thalidomide, cereblon and multiple myeloma].
    Ogura T
    Nihon Rinsho; 2015 Jan; 73(1):149-55. PubMed ID: 25626321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A clinical review and introduction of the diagnostic algorithm for thalidomide embryopathy (DATE).
    Mansour S; Baple E; Hall CM
    J Hand Surg Eur Vol; 2019 Jan; 44(1):96-108. PubMed ID: 30253685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.